Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 818
  • Home
  • Print this page
  • Email this page

    Article Cited by others

ORIGINAL ARTICLE

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration

Biswas Partha, Sengupta Subhrangshu, Choudhary Ruby, Home Subhankar, Paul Ajoy, Sinha Sourav

Year : 2011| Volume: 59| Issue : 3 | Page no: 191-196

   This article has been cited by
 
1 BEVACIZUMAB VERSUS RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Guohai Chen,Wensheng Li,Radouil Tzekov,Fangzheng Jiang,Sihong Mao,Yuhua Tong
Retina. 2015; 35(2): 187
[Pubmed]  [Google Scholar] [DOI]
2 Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview
Francesco Semeraro,Francesco Morescalchi,Sarah Duse,Elena Gambicorti,Mario R Romano,Ciro Costagliola
Expert Opinion on Drug Safety. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]
3 Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab
S. Jiang,C. Park,J. C. Barner
Journal of Clinical Pharmacy and Therapeutics. 2014; : n/a
[Pubmed]  [Google Scholar] [DOI]
4 Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration
Davin Johnson,Sanjay Sharma
Current Opinion in Ophthalmology. 2013; 24(3): 205
[Pubmed]  [Google Scholar] [DOI]
5 Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
Usha Chakravarthy,Simon P Harding,Chris A Rogers,Susan M Downes,Andrew J Lotery,Lucy A Culliford,Barnaby C Reeves
The Lancet. 2013; 382(9900): 1258
[Pubmed]  [Google Scholar] [DOI]
6 Bevacizumab for the treatment of neovascular age-related macular degeneration | [Bevacizumab para el tratamiento de degeneración macular neovascular relacionada con la edad]
Pitlick, J.M., Vecera, K.F., Barnes, K.N., Reski, J.W., Forinash, A.B.
Annals of Pharmacotherapy. 2012; 46(2): 290-296
[Pubmed]  [Google Scholar]
7 Dilemma of Avastin application and medical administration policy
Xu, L., Li, J.-J., You, Q.-S.
Ophthalmology in China. 2011; 20(5): 289-291
[Pubmed]  [Google Scholar]

 

Read this article